Industry Roundup: FPLA changes; Nutroganics in soy market; spiked product, supplement-beverage warnings; Kamil chairs CRN
This article was originally published in The Tan Sheet
Executive Summary
FPLA changes proposed; Nutroganics invests to reach soy market; Shoreside hits spiked ingredient trifecta; NYSW blurs supplement-beverage line; Kamil elected CRN chair; and more news in brief.
You may also be interested in...
Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance
FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.